Literatur
-
1
Arolt V, Rothermundt M.
Depressive Störungen bei körperlich Kranken.
Nervenarzt.
2003;
74
1033-1052
-
2
Felker B, Yazel J J, Short D.
Mortality and medical comorbidity among psychiatric patients: a review.
Psychiatr Serv.
1996;
47
1356-1363
-
3 Hewer W. Psychische Störungen und internistische Erkrankungen. Helmchen H et al Psychiatrie der Gegenwart. 4. Aufl., Band 4: Psychische Störungen bei somatischen Erkrankungen. Berlin Heidelberg New York; Springer 1999: 289-317
-
4
Fleischhacker W W, Cetkovich-Bakmas M, De Hert M. et al .
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.
J Clin Psychiatry.
2008;
69
514-519
-
5
Iacovides A, Siamouli M.
Comorbid mental and somatic disorders: an epidemiological perspective.
Curr Opin Psychiatry.
2008;
21
417-421
-
6
Dalmau A, Bergman B, Brismar B.
Somatic morbidity in schizophrenia – a case control study.
Public Health.
1997;
111
393-397
-
7
Mäkikyrö T, Karvonen J T, Hakko H. et al .
Comorbidity of hospital-treated psychiatric and physical disorders with special reference to schizophrenia: a 28 year follow-up of the 1966 northern Finland general population birth cohort.
Public Health.
1998;
112
221-228
-
8
Goldman L S.
Medical illness in patients with schizophrenia.
J Clin Psychiatry.
1999;
60 (Suppl 21)
10-15
-
9
Carney C P, Jones L, Woolson R F.
Medical comorbidity in women and men with schizophrenia: a population-based controlled study.
J Gen Intern Med.
2006;
21
1133-1137
-
10
Leucht S, Burkard T, Henderson J. et al .
Physical illness and schizophrenia: a review of the literature.
Acta Psychiatr Scand.
2007;
116
317-333
-
11
Carney C P, Jones L E.
Medical comorbidity in women and men with bipolar disorders: a population-based controlled study.
Psychosom Med.
2006;
68
684-691
-
12
McIntyre R S, Soczynska J K, Beyer J L. et al .
Medical comorbidity in bipolar disorder: re-prioritizing unmet needs.
Curr Opin Psychiatry.
2007;
20
406-416
-
13
Glassman A.
Depression and cardiovascular disease.
Pharmacopsychiatry.
2008;
41
221-225
-
14
Batki S L, Meszaros Z S, Strutynski K. et al .
Medical comorbidity in patients with schizophrenia and alcohol dependence.
Schizophr Res.
2008;
DOI: 10.1016 /j.schres.2008.10.016
-
15
Frankenburg F R, Zanarini M C.
Personality disorders and medical comorbidity.
Curr Opin Psychiatry.
2006;
19
428-431
-
16
Jeste D V, Gladsjo J A, Lindamer L A. et al .
Medical comorbidity in schizophrenia.
Schiz Bull.
1996;
22
413-430
-
17
Koran L M, Sox H C, Marton K I. et al .
Medical evaluation of psychiatric patients.
Arch Gen Psychiat.
1989;
46
733-740
-
18
Koranyi E K.
Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population.
Arch Gen Psychiat.
1979;
36
414-419
-
19
Reeves R R, Pendarvis E J, Kimble R.
Unrecognized medical emergencies admitted to psychiatric units.
Am J Emerg Med.
2000;
18
390-393
-
20
Harris C E, Barraclough B.
Excess mortality of mental disorder.
Brit J Psychiat.
1998;
173
11-53
-
21
Saha S, Chant D, McGrath J.
A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?.
Arch Gen Psychiatry.
2007;
64
1123-1131
-
22
Ösby U, Brandt L, Correia N. et al .
Excess mortality in bipolar and unipolar disorder in Sweden.
Arch Gen Psychiat.
2001;
58
844-850
-
23
Bartels S J.
Caring for the whole person: integrated health care for older adults with severe mental illness and medical comorbidity.
J Am Geriatr Soc.
2004;
52
S249-S257
-
24
Hennekens C H, Hennekens A R, Hollar D. et al .
Schizophrenia and increased risks of cardiovascular disease.
Am Heart J.
2005;
150
1115-1121
-
25
Lambert T J, Velakoulis D, Pantelis C.
Medical comorbidity in schizophrenia.
Med J Austr.
2003;
178
S67-S70
-
26
Allebeck P.
Schizophrenia: a life-shortening disease.
Schizophr Bull.
1989;
15
81-89
-
27 Casey D E, Hansen T E. Excessive mortality and morbidity associated with schizophrenia. Meyer JM, Nasrallah HA Medical illness in schizophrenia Washington DC & London; American Psychiatric Publishing 2003: 13-34
-
28
Lawrence D, Holman C D, Jablensky A V. et al .
Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980 – 1998.
Brit J Psychiat.
2003;
182
31-36
-
29
Rasanen S, Hakko H, Viilo K. et al .
Excess mortality among long-stay psychiatric patients in Northern Finland.
Soc Psychiatry Psychiatr Epidemiol.
2003;
38
297-304
-
30
Osborn D PJ, Levy G, Nazareth I. et al .
Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s general practice research database.
Arch Gen Psychiatry.
2007;
64
242-249
-
31
Ösby U, Correia N, Brandt L. et al .
Mortality and causes of death in schizophrenia in Stockholm county, Sweden.
Schizophr Res.
2000;
45
21-28
-
32
Antretter E, Dunkel D, Haring C.
Cause-specific excess mortality in suicidal patients: gender differences in mortality patterns.
Gen Hosp Psychiatry.
2009;
31
67-74
-
33
Carter G, Reith D M, Whyte I M. et al .
Non-suicidal deaths following hospital-treated self-poisoning.
Aust NZ J Psychiatry.
2005;
39
101-107
-
34
Hamer M, Stamatakis E, Steptoe A.
Psychiatric hospital admissions, behavioral risk factors, and all-cause mortality: the Scottish health survey.
Arch Intern Med.
2008;
168
2474-2479
-
35
Hewer W, Rössler W, Jung E. et al .
Somatische Erkrankungen bei stationär behandelten psychiatrischen Patienten.
Psychiat Prax.
1991;
18
133-138
-
36 Wolff H P, Weihrauch T R. Internistische Therapie 2008 / 2009. München; Elsevier 2008 17. Aufl
-
37
Curkendall S M, Mo J, Glasser D B. et al .
Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada.
J Clin Psychiatry.
2004;
65
715-720
-
38
Mitchell A J, Malone D.
Physical health and schizophrenia.
Curr Opin Psychiatry.
2006;
19
432-437
-
39
Ruschena D, Mullen P E, Burgess P. et al .
Sudden death in psychiatric patients.
Br J Psychiatry.
1998;
172
331-336
-
40
Schneeweiss S, Avorn J.
Antipsychotic agents and sudden cardiac death – how should we manage the risk?.
N Engl J Med.
2009;
360
294-296
-
41
Ray W A, Chung C P, Murray K T. et al .
Atypical antipsychotic drugs and the risk of sudden cardiac death.
N Engl J Med.
2009;
360
225-235
-
42
Haverkamp W, Deuschle M.
Antipsychotikainduzierte QT-Verlängerung.
Nervenarzt.
2006;
77
276-288
-
43
Reilly J G, Ayis S A, Ferrier I N.
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.
Lancet.
2000;
355
1048-1052
-
44 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Heidelberg–Berlin; Springer 2009 7. Aufl
-
45
Agelink M W, Kornischka J, Cordes J. et al .
Allgemeinmedizinische Aspekte der Therapie mit Antipsychotika der zweiten Generation.
Dtsch Ärztebl.
2006;
103
2802-2808
-
46 Hewer W, Grohmann R. Akut- und Notfallsituationen durch unerwünschte Arzneimittelwirkungen (UAW). Hewer W, Rössler W Akute psychische Erkrankungen München; Elsevier 2007 2. Aufl: 467-499
-
47
Blaschke D, Parwani A S, Huerner M. et al .
Torsade de pointes during combined treatment with risperidone and citalopram.
Pharmacopsychiatry.
2007;
40
294-295
-
48 Deutsche Hochdruckliga – Deutsche Hypertonie Gesellschaft .Leitlinien zur Behandlung der arteriellen Hypertonie. 2008 http://leitlinien.net/
-
49
Goff D C, Sullivan L M, McEvoy J P. et al .
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.
Schizophrenia Research.
2005;
80
45-53
-
50
Hägg S, Spigset O.
Antipsychotic-induced venous thromboembolism: a review of the evidence.
CNS Drugs.
2002;
16
765-776
-
51
Maly R, Masopust J, Hosak L. et al .
Assessment of the risk of venous thrombembolism and its possible prevention in psychiatric patients.
Psychiatry Clin Neurosci.
2008;
62
3-8
-
52
Lacut K, Le Gal G, Couturaud F. et al .
Association between antipsychotic drugs, antidepressant drugs and venous thrombembolism: results from the EDITH case-control study.
Fundam Clin Pharmacol.
2007;
21
643-650
-
53
Hach-Wunderle V.
Diagnostik und Therapie der venösen Thrombose.
Hämostaseologie.
2008;
28
376-386
-
54
Konstantinides S.
Venöse Thrombembolie.
Dtsch Med Wschr.
2006;
131
1389-1400
-
55
Goff D C, Heckers S, Freudenreich O.
Schizophrenia.
Med Clin North Am.
2001;
85
663-689
-
56 Programm für Nationale Versorgungs-Leitlinien. Nationale VersorgungsLeitlinie COPD Kurzfassung. 2006 http://leitlinien.net/
-
57 AWMF-Leitlinie Nr.082 / 001. Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen tiefen Atemwegsinfektionen (akute Bronchitis, akute Exazerbation einer chronischen Bronchitis, Influenza und andere respiratorische Virusinfektionen) sowie ambulant erworbener Pneumonie. 2005 http://leitlinien.net/
-
58
Fioritti A, Giacotto L, Melega V.
Choking incidents among psychiatric patients: retrospective analysis of thirty-one cases from the West Bologna psychiatric wards.
Can J Psychiatry.
1997;
42
515-520
-
59
Schmitt M F, Hewer W.
Lebensbedrohliche Situationen durch Bolusaspiration bei stationär behandelten psychisch Kranken – Klinik, Risikofaktoren, Prophylaxe, Therapie.
Fortschr Neurol Psychiat.
1993;
61
313-318
-
60
Mortensen P B, Juel K.
Mortality and causes of death in schizophrenic patients in Denmark.
Acta Psychiatr Scand.
1990;
81
372-377
-
61
Ruschena D, Mullen P E, Palmer S. et al .
Choking death: the role of antipsychotic drugs.
Br J Psychiatry.
2003;
183
446-450
-
62
Winkelman J W.
Schizophrenia, obesity, and obstructive sleep apnea.
J Clin Psychiatry.
2001;
62
8-11
-
63
Catts V S, Catts S V, O`Toole B I. et al .
Cancer incidence in patients with schizophrenia and their first-degree relatives – a meta-analysis.
Acta Psychiatr Scand.
2008;
117
323-336
-
64
Lawrence D, Holman C D, Jablensky A V. et al .
Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates.
Acta Psychiatr Scand.
2000;
101
382-388
-
65
Marder S R, Essock S M, Miller A L. et al .
Physical health monitoring of patients with schizophrenia.
Am J Psychiatry.
2004;
161
1334-1349
-
66 Hauner H, Buchholz G, Hamann A. et al .Evidenzbasierte Leitlinie. Prävention und Therapie der Adipositas. 2007 http://leitlinien.net/
-
67
Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).
JAMA.
2001;
285
2486-2497
-
68
Alberti K G, Zimmet P, Shaw J. et al .
The metabolic syndrome – a new worldwide definition.
Lancet.
2005;
366
1059-1062
-
69
Hummer M, Kemmler G, Kurz M. et al .
Weight gain induced by clozapine.
Eur Neuropsychopharmacol.
1995;
5
437-440
-
70
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity .
Consensus development conference on antipsychotic drugs and obesity and diabetes.
Diabetes Care.
2004;
27
596-601
-
71 Kopf D. Diabetes mellitus bei psychiatrischen Erkrankungen. Schatz H Diabetologie kompakt Stuttgart; Georg-Thieme-Verlag 2006 4. Aufl: 320-325
-
72
Smith M, Hopkins D, Peveler R C. et al .
First- v. Second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and metaanalysis.
Br J Psychiatry.
2008;
192
406-411
-
73
Holt R IG, Peveler R C, Byrne C D.
Schizophenia, the metabolic syndrome and diabetes.
Diabet Med.
2004;
21
515-523
-
74
Kerner W, Brückel J.
Definition, Klassifikation und Diagnostik des Diabetes mellitus.
Diabetologie.
2008;
3 Suppl 2
S131-S133
-
75
Von Hayek D, Hüttl V, Reiss J. et al .
Hyperglykämie und Ketoazidose unter Olanzapin.
Nervenarzt.
1999;
70
836-837
-
76
Hummer M, Malik P, Gasser R W. et al .
Osteoporosis in patients with schizophrenia.
Am J Psychiatry.
2005;
162
162-167
-
77
Siegel A J.
Hyponatremia in psychiatric patients: update on evaluation and management.
Harv Rev Psychiatry.
2008;
16
13-24
-
78
Scholze A, Tepel M.
Hyponatriämie.
Med Klin.
2009;
104
137-149
-
79
Brookes G, Ahmed AG. Pharmacologic treatments for psychosis-related polydipsia.
Cochrane Database Syst Rev.
2006;
CD003544
-
80
Dundas B, Harris M, Narasimhan M.
Psychogenic polydipsia review: etiology, differential, and treatment.
Curr Psychiatry Rep.
2007;
9
236-241
-
81 Hewer W. Körperliche Erkrankungen bei psychiatrischen Patienten. Arolt V, Diefenbacher A Psychiatrie in der klinischen Medizin Darmstadt; Steinkopff 2004: 241-258
-
82
Grohmann R, Müller-Oerlinghausen B, Rüther E. et al .
25 years of drug surveillance in psychiatry.
Pharmacopsychiatry.
2004;
37
Suppl 1
-
83
Brown S.
Excess mortality of schizophrenia: a meta-analysis.
Brit J Psychiat.
1997;
171
502-508
-
84
Weeke A, Juel K, Vaeth M.
Cardiovascular death and manic-depressive psychosis.
J Affect Disord.
1987;
13
287-292
-
85
Ahrens B, Grof P, Möller H J. et al .
Extended survival of patients on long-term lithium treatment.
Can J Psychiatry.
1995;
40
241-246
-
86
Tiihonen J, Wahlbeck K, Lönnqvist J. et al .
Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
BMJ.
2006;
333
224-227
-
87 Eckermann G. Interaktionstabellen Psychopharmaka. Stuttgart; Schattauer 2006
4 Herrn Dr. med. Hans Werner Schied in dankbarer Verbundenheit gewidmet.
Priv.-Doz. Dr. med. Walter Hewer
Vinzenz-von-Paul-Hospital
Schwenninger Str. 55
78628 Rottweil
Email: w.hewer@VvPH.de
